Literature DB >> 16325975

Incremental cost-effectiveness ratios (ICERs): the silence of the lambda.

Amiram Gafni1, Stephen Birch.   

Abstract

Despite the central role of the threshold incremental cost-effectiveness ratio (ICER), or lambda (lambda), in the methods and application of cost-effective analysis (CEA), little attention has been given to the determining the value of lambda. In this paper we consider 'what explains the silence of the lambda'? The concept of the threshold ICER is critically appraised. We show that there is 'silence of the lambda' with respect to justification of the value of ICER thresholds, their use in decision-making and their relationship to the opportunity cost of marginal resources. Moreover, the 'sound of silence' extends to both 'automatic cut-off' and more sophisticated approaches to the use of lambda in determining recommendations about health care programs. We argue that the threshold value provides no useful information for determining the efficiency of using available resources to support new health care programs. On the contrary, the threshold approach has lead to decisions that resulted in increased expenditures on health care programs and concerns about the sustainability of public funding for health care programs without any evidence of increases in total health gains. To improve efficiency in resource allocation, decision-makers need information about the opportunity costs of programs.

Mesh:

Year:  2005        PMID: 16325975     DOI: 10.1016/j.socscimed.2005.10.023

Source DB:  PubMed          Journal:  Soc Sci Med        ISSN: 0277-9536            Impact factor:   4.634


  62 in total

1.  Selecting a mix of prevention strategies against cervical cancer for maximum efficiency with an optimization program.

Authors:  Nadia Demarteau; Thomas Breuer; Baudouin Standaert
Journal:  Pharmacoeconomics       Date:  2012-04       Impact factor: 4.981

2.  A game-theoretic framework for estimating a health purchaser's willingness-to-pay for health and for expansion.

Authors:  Reza Yaesoubi; Stephen D Roberts
Journal:  Health Care Manag Sci       Date:  2010-08-12

3.  What is the value of oncology medicines?

Authors:  Joshua Cohen; William Looney
Journal:  Nat Biotechnol       Date:  2010-11       Impact factor: 54.908

4.  The Irish Cost-Effectiveness Threshold: Does it Support Rational Rationing or Might it Lead to Unintended Harm to Ireland's Health System?

Authors:  James F O'Mahony; Diarmuid Coughlan
Journal:  Pharmacoeconomics       Date:  2016-01       Impact factor: 4.981

5.  Should the Lambda (λ) Remain Silent?

Authors:  Hossein Haji Ali Afzali; Jonathan Karnon; Mark Sculpher
Journal:  Pharmacoeconomics       Date:  2016-04       Impact factor: 4.981

Review 6.  Information created to evade reality (ICER): things we should not look to for answers.

Authors:  Stephen Birch; Amiram Gafni
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

7.  Economic evidence at the local level : options for making it more useful.

Authors:  Kees van Gool; Gisselle Gallego; Marion Haas; Rosalie Viney; Jane Hall; Robyn Ward
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

8.  The new myth: the social value of the QALY.

Authors:  Werner Brouwer; Job van Exel; Rachel Baker; Cam Donaldson
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

9.  Building bridges between academic research and policy formulation: when costing less means costing more.

Authors:  Amiram Gafni; Stephen Birch
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

10.  Economic evaluation of osteoporosis liaison service for secondary fracture prevention in postmenopausal osteoporosis patients with previous hip fracture in Japan.

Authors:  K Moriwaki; S Noto
Journal:  Osteoporos Int       Date:  2016-10-04       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.